Skip to content

PP&E (Net) at other companies

Pfizer logo
PfizerPFE
$19.4B+5.8%
Eikon Therapeutics, Inc.
 logo
Eikon Therapeutics, Inc. EIKN
$138.07M
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Replimune Group logo
Replimune GroupREPL
$13.85M+1.7%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$8.63M-2.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$12.61M-19.1%

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s PP&E (net)?
OnKure Therapeutics, Inc. (OKUR) reported PP&E (net) of $519K in Q1 2026.
How has OnKure Therapeutics, Inc.'s PP&E (net) changed year-over-year?
OnKure Therapeutics, Inc.'s PP&E (net) decreased by 43.9% year-over-year, from $925K to $519K.
What is the long-term trend for OnKure Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), OnKure Therapeutics, Inc.'s PP&E (net) has grown at a 55.0% compound annual growth rate (CAGR), from $69K to $618K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.